People with von Willebrand disease can be susceptible to spontaneous and traumatic bleeding, including:
wilate® efficacy rated ‘excellent’ or ‘good’
of 1095 treated bleeding events
WIL-20 included 111 patients (aged 1 to 83 years) at 31 centers. 29 patients were treated on-demand with wilate®
wilate® efficacy rated ‘excellent’ or ‘good’ in
of 127 treated bleeding events*
wilate® efficacy rated ‘excellent’ or ‘good’
of 46 bleeding events in 25 adults (median age 42 years, range 19–82 years)4
of 44 bleeding events in 15 adolescents and children (median age 7 years, range 0–17 years)5
de Wee EM et al. Thromb Haemost 2012; 108:683–92.
Berntorp E et al. Haemophilia 2009; 15:122–30.
Sholzberg M et al. TH Open 2021; 5:e264–72.
Batty P et al. Haemophilia 2014; 20:846–53.
Miesbach W and Berntorp E. Thromb Res 2021; 199:67–74.
Khair K et al. Haemophilia 2015; 21:e44–50.
Lillicrap D and James P. WFH Treatment of Hemophilia 2009; No. 47 (available at this link)
Castaman G et al. Haematologica 2013; 98:667–74.
Please see wilate® full Prescribing Information.
Indication
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.
Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
Adverse Reactions
The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).
Please see wilate® full Prescribing Information.
Please see wilate® full Prescribing Information.
Indication
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.
Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
Adverse Reactions
The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).
Please see wilate® full Prescribing Information.
Octapharma does not review, endorse, or control the content of any non-Octapharma site. Octapharma is not responsible for the accuracy, content, practices, or standards of any non-Octapharma resources accessed through a link on this site. Octapharma provides general information for educational purposes. This site does not provide medical advice, diagnosis, or treatment to you. Always consult your physician to help decide a treatment plan or other medical advice.
The information on this website has been specifically created for U.S. healthcare professionals (HCPs)
Please see wilate® full Prescribing Information